Clinical research often lacks sufficient evidence, leading to prescribing decisions in healthcare that are not evidence-based or supported by randomized, double-blind clinical trials. This is one of the reasons why drug development takes a significant amount of time and financial resources, with an average cost of $3 billion and a duration of 12 years.
To address this issue, it is crucial to support sponsors in achieving their desired outcomes by establishing a more efficient pathway for them to develop tools, integrate data-collecting sensors and generate the necessary evidence. By implementing a unified clinical trial data collection platform powered by intelligent automation, we can expedite startup timelines, standardize the collection of digital measurements and facilitate the creation of innovative trial designs and endpoints, positively impacting the delivery of clinical trials and drug programs.
In this webinar, industry experts will discuss how combining a unified clinical trial data collection platform with intelligent automation can revolutionize drug development and why the current status quo is no longer sufficient. With these capabilities, the industry now has the opportunity to explore new possibilities, such as incorporating additional sensors to identify surrogate or alternative endpoints, rethinking adaptive trial designs and efficiently responding to emerging data.
Musaddiq Khan, VP, Therapeutic Area Solutions Leader, Medable
Musaddiq Khan (“Muz”) has been involved in clinical research for over 17 years. Most recently, he was the Director of Clinical Program Operations in the Exploratory Medicine & Pharmacology group at Eli Lilly, where he led the operational delivery of the first-in-human study on Lilly’s COVID-19 Antibody program. Throughout his career, Muz has held various clinical operations roles in pharma, including Parexel, Roche and AstraZeneca. Muz completed his Executive MBA from the University of Cambridge with a dissertation on “Developing a Digital Health Strategy for Early Clinical Development.”
Cindy Howry, VP, eCOA Science, Medable
Cindy Howry is a nationally recognized thought-leader in the area of electronic Clinical Outcome Assessments (eCOA) and digital physiological measures which empowers the patient and engages them to maintain and improve their health, simultaneously enabling clinical teams to have real-time access to better quality clinical data. Ms. Howry has more than 35 years of experience in management and leadership, including 21 years in clinical research.
She is Vice-President, eCOA Science at Medable. Previously, she was CEO for assisTek, a leading-edge company providing eSource solutions for healthcare and clinical research; in addition, she is served three terms in the elected position of Vice-Director for ePRO Consortium at C-PATH, a group of eCOA companies working in a non-competitive environment to advance the quality, practicality, and acceptability of electronic data capture (EDC) methods used in clinical trials for PRO endpoint assessment.
Her experience prior to joining assisTek includes leadership roles of VP, Product Strategy and Innovation at YPrime, Principal, eCOA Solutions at Bracket Global, VP Client Services at Arrowhead Electronic Healthcare, and Manager of Client Services at assisTek. She was also Professor, Computer Science at Collin College for 13 years. Ms. Howry earned both B.S. in Counselor Education and M.S. in Computer Science at the University of North Texas.
She enjoys spending time with family, gardening, and listening to music in Austin.
Sarah Valentine, Partnerships Lead, Life Sciences, Digital Medicine Society (DiMe)
Sarah Valentine leads partnerships across life sciences at the Digital Medicine Society (DiMe). In her role, she thinks critically about the challenges we face in drug development and commercialization to drive strategy, prioritization, and concept development across areas of unmet need where there’s an opportunity at the intersection of healthcare and technology to deliver unprecedented value to patients and other stakeholders across our industry. She convenes teams of interdisciplinary thought leaders and subject matter experts to tackle some of the biggest challenges we face as a field in order to advance the ethical, effective, equitable, and safe use of digital medicine to redefine healthcare and improve lives. Prior to her role at DiMe, Sarah was a digital implementation lead at Eli Lilly & Company, where she led efforts at the intersection of clinical development and digital health to leverage innovative digital technologies and capabilities including digital measures, combination products, and other DDTs in clinical research.
Who Should Attend?
- Large Pharma and Biotech
- Mid-Market Pharma and Biotech
- Clinical Operations/Clinical Development
- eCOA/ePRO leads
- Therapeutic Area leads
- Clinical Data Strategy
- Data Management/Processing/Analysis/Data Science
- Trial Innovation/Management
- Trial Optimization
- Digital Innovation/Decentralized Trials/Clinical Innovation
- Real-World Evidence/Real-World Data
- Clinical IT
- Clinical Systems
What You Will Learn
Attendees will gain insights into:
- How intelligent automation can expedite startup timelines while being responsive to any required changes
- Demonstration of the effectiveness of a unified clinical trial data collection platform in enabling evidence generation through industry-level use cases
- Why a collaborative approach between regulators, sponsors and technology vendors is essential to define what is feasible and acceptable in a modern clinical environment
Medable is on a mission to get effective therapies to patients faster by transforming clinical drug development with disruptive technologies. The company’s digital platform streamlines design, recruitment, retention and data quality for decentralized trials, replacing siloed systems with integrated digital tools, data and interfaces to accelerate trial execution. Medable connects patients, sites and clinical trial teams to improve patient access, experience and outcomes.